arrow
Back
N

Nicholas C. Turner

Royal Marsden Hospital and Institute of Cancer Research

92H-index
1.2KPaper Count
4.5WCitation Count
Published Papers 256
Publication Date
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
err2026-07-13
err0
PREAI
errNicholas C Turner; Erica L Mayer; Yeon Hee Park; Wolfgang Janni; Cynthia Ma; Massimo Cristofanilli; Giampaolo Bianchini; Kevin Kalinsky; Hiroji Iwata; Stephen Chia; Adam M Brufsky; Peter A Fasching; Zbigniew Nowecki; Javier Pascual; Nuri Karadurmus; Einav Gal-Yam; Wei-Pang Chung; Seock-Ah Im; Alberto Zambelli; Florence Dalenc
errShare
errSave
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2− locally-advanced or metastatic breast cancer
err2026-04-01
err0
errOAAI
errJackson Liang; Christy Ong; Kareem Heslop; Jane Guan; Vasumathi Kameswaran; Bence Daniel; Minyi Shi; Yuxin Liang; Jennifer M. Giltnane; Junko Aimi; Ching-Wei Chang; Mary R. Gates; Jennifer Eng-Wong; Pablo Perez-Moreno; Komal L. Jhaveri; Nicholas C. Turner; Elgene Lim; Ciara Metcalfe; Heather M. Moore
errShare
errSave
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
errNature
IF48.5
err2026-03-04
err0
errOAAI
errAnton Safonov; Minna Lee; David N. Brown; Luca Boscolo Bielo; Miika Mehine; Chaitanya Bandlamudi; Ben O’Leary; Hong Shao; Laia Vicente; Daniel Muldoon; Allen Zhu; Susana Ros; Antonio Marra; Pier Selenica; Ivan Bieche; Bradley Wubbenhorst; Emanuela Ferraro; Laura Courtois; Rania El Botty; Mehnaj Ahmed; Enrico Moiso; Julia Ah-Reum An; Mark T. A. Donoghue; Marie Will; Fresia Pareja; Emily Nizialek; Natalia Lukashchuk; Eleni Sofianopoulou; Yuan Liu; Xin Huang; Colombe Chappey; Anna D. Staniszewska; Dara Ross; Diana Mandelker; Marc Ladanyi; Nikolaus Schultz; Michael F. Berger; Maurizio Scaltriti; Jorge S. Reis-Filho; Bob T. Li; Kenneth Offit; Larry Norton; Ronglai Shen; Kara N. Maxwell; Fergus Couch; Susan M. Domchek; Elisabetta Marangoni; Sohrab Shah; Mark R. Albertella; Violeta Serra; Britta Weigelt; David B. Solit; Katherine L. Nathanson; Mark E. Robson; Nicholas C. Turner; Sarat Chandarlapaty; Pedram Razavi
errShare
errSave
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy
err2025-10-20
err0
errOAAI
errE.L. Mayer; F.-C. Bidard; Y.H. Park; W. Janni; C. Ma; M. Cristofanilli; H. Iwata; G. Bianchini; K. Kalinsky; S. Chia; A. Brufsky; P.A. Fasching; Z. Nowecki; S.-C. Chen; J. Pascual; L. Moreau; M. Ruiz-Borrego; A. Shai; N. Karadurmus; J.H. Sohn; Y. Zhu; I. Leddin; M.S. Miralles; C.H. Bartlett; N. Turner
errShare
errSave
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis
err2025-10-07
err0
errOAAI
errDaniella Black; Helen Ruth Davies; Gene Ching Chiek Koh; Lucia Chmelova; Marko Cubric; Georgia Chalivelaki Chan; Andrea Degasperi; Jan Czarnecki; Ping Jing Toong; Yasin Memari; James Whitworth; Salome Jingchen Zhao; Yogesh Kumar; Shadi Basyuni; Giuseppe Rinaldi; Scott Shooter; Vladyslav Dembrovskyi; Rosie Davies; Maria Chatzou Dunford; Ellen Copson; Carlo Palmieri; Åke Borg; John Ambrose; Catey Bunce; Alona Sosinsky; Prabhu Arumugam; Matthew Arthur Brown; Johan Staaf; Nicholas Turner; Serena Nik-Zainal
errShare
errSave
ENDOCANNABINOIDS AND INTRUSIVE MEMORIES: EVIDENCE FOR A ROLE OF ANANDAMIDE FROM TWO EXPERIMENTAL HUMAN STUDIES
err2025-08-01
err0
errOAAI
errNey, L.; Jarvis, M.; Hamzah, K. Amir; Hsu, K. C. M.; Zuj, D.; Nicholson, E.; Felmingham, K.; Lipp, O.; Turner, N.; Nichols, D.; Bruno, R.; Matthews, A.
errShare
errSave
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
err2025-07-01
err0
PREAI
errV. Gambardella; M.K. Accordino; P.L. Bedard; A. Cervantes; E. Hamilton; A. Italiano; K. Kalinsky; I.E. Krop; M. Oliveira; C. Saura; P. Schmid; N.C. Turner; A. Varga; A. Fernandez-Saranillo; Y. Jin; S. Royer-Joo; U. Peters; N. Shankar; J.L. Schutzman; D. Juric; K.L. Jhaveri
errShare
errSave
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
err2025-05-09
err0
errOAAI
errHu, Xichun; Zhang, Qingyuan; Sun, Tao; Xiong, Huihua; Li, Wei; Teng, Yuee; Lu, Yen-Shen; Tseng, Ling-Ming; Yan, Min; Li, Hongsheng; Pang, Danmei; -Chen, Shin-Cheh; Chen, Wenyan; Jiang, Ou; Wang, Jingfen; Wu, Xinhong; Wang, Xian; Zang, Aimin; Wang, Xiaojia; Collins, Julie M.; Fan, Ethan; Jiang, Lin; Zeng, Xiaoling; Turner, Nicholas C.
errShare
errSave
Prognostic Utility of ctDNA Detection in The monarchE Trial of Adjuvant Abemaciclib Plus Endocrine therapy (ET) in HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC)
errBREAST
IF7.9
err2025-02-01
err0
errOAAI
errLoi, S.; Johnston, S.; Arteaga, C.; Graff, S.; Chandarlapaty, S.; Goetz, M.; Desmedt, C.; Sasano, H.; Liu, D.; Rodrik-Outmezguine, V.; Sireci, A.; Sandoval, C.; Won, H.; Litchfield, L.; Turner, N.
errShare
errSave
Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial
errBREAST
IF7.9
err2025-02-01
err0
errOAAI
errRubenstein, C. S.; Turner, N.; Reis-Filho, J. S.; Goetz, M. P.; Desmedt, C.; Chandarlapaty, S.; Sasano, H.; Arteaga, C. L.; Loi, S.; Graff, S. L.; Liu, D.; Rodrik-Outmezguine, V.; Sireci, A.; Won, H.; Litchfield, L. M.; Munoz, M.; Johnston, S.
errShare
errSave
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
err2024-11-05
err0
errOAAI
errHerrera-Abreu, M. T.; Guan, J.; Khalid, U.; Ning, J.; Costa, M. R.; Chan, J.; Li, Q.; Fortin, J-p.; Wong, W. R.; Perampalam, P.; Biton, A.; Sandoval, W.; Vijay, J.; Hafner, M.; Cutts, R.; Wilson, G.; Frankum, J.; Roumeliotis, T. I.; Alexander, J.; Hickman, O.; Brough, R.; Haider, S.; Choudhary, J.; Lord, C. J.; Swain, A.; Metcalfe, C.; Turner, N. C.
errShare
errSave
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
err2024-10-31
err3
PREAI
errTurner, N. C.; Im, S-A; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Sunpaweravong, P.; Musolino, A.; Li, H.; Zhang, Q.; Nowecki, Z.; Leung, R.; Thanopoulou, E.; Shankar, N.; Lei, G.; Stout, T. J.; Hutchinson, K. E.; Schutzman, J. L.; Song, C.; Jhaveri, K. L.
errShare
errSave
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer
err2024-10-18
err1
errOAAI
errGarcia-Murillas, Isaac; Cutts, Rosalind J.; Walsh-Crestani, Giselle; Phillips, Edward; Hrebien, Sarah; Dunne, Kathryn; Sidhu, Kally; Daber, Robert; Hubert, Benjamin; Graybill, Chiharu; Deford, Peter M.; Wooten, David J.; Zhao, Jianhua; Ellsworth, Rachel E.; Johnston, Stephen R. D.; Ring, Alistair; Russell, Simon; Evans, Abigail; Skene, Anthony; Wheatley, Duncan; Smith, Ian E.; Korn, W. Michael; Turner, Nicholas C.
errShare
errSave
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer
err2024-09-16
err2
errOAAI
errTurner, Nicholas C.; Oliveira, Mafalda; Howell, Sacha J.; Dalenc, Florence; Cortes, Javier; Gomez, Henry L.; Hu, Xichun; Jhaveri, Komal; Krivorotko, Petr; Loibl, Sibylle; Murillo, Serafin Morales; Park, Yeon Hee; Sohn, Joo-Hyuk; Toi, Masakazu; Tokunaga, Eriko; Yousef, Samih; Zhukova, Lyudmila; de Bruin, Elza; Grinsted, Lynda; Schiavon, Gaia; Foxley, Andrew; Rugo, Hope S.
errShare
errSave
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
err2024-09-01
err3
errOAAI
errRugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Jhaveri, K. L.; Krivorotko, P.; Loibl, S.; Murillo, S. Morales; Nowecki, Z.; Okera, M.; Park, Y. H.; Sohn, J.; Toi, M.; Iwata, H.; Yousef, S.; Zhukova, L.; Logan, J.; Twomey, K.; Khatun, M.; D'Cruz, C. M.; Turner, N. C.
errShare
errSave
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?
err2024-09-01
err2
errOAAI
errValenza, C.; Trapani, D.; Bidard, F. -c.; Gligorov, J.; Cortes, J.; Turner, N.; Dalenc, F.; Penault-Llorca, F.; Freyer, G.; Arnedos, M.; Villanueva, C.; Loibl, S.; Pistilli, B.; Curigliano, G.
errShare
errSave
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
err2024-08-01
err6
errOAAI
errHamilton, E.; Oliveira, M.; Turner, N.; Garcia-Corbacho, J.; Hernando, C.; Ciruelos, E. M.; Kabos, P.; Ruiz-Borrego, M.; Armstrong, A.; Patel, M. R.; Vaklavas, C.; Twelves, C.; Boni, V.; Incorvati, J.; Brier, T.; Gibbons, L.; Klinowska, T.; Lindemann, J. P. O.; Morrow, C. J.; Sykes, A.; Baird, R. D.
errShare
errSave
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial
err2024-07-26
err0
errOAAI
errDent, Rebecca A.; Kim, Sung-Bae; Oliveira, Mafalda; Barrios, Carlos; O'Shaughnessy, Joyce; Isakoff, Steven J.; Saji, Shigehira; Freitas-Junior, Ruffo; Philco, Manuel; Bondarenko, Igor; Lian, Qinshu; Bradley, Denise; Hinton, Heather; Wongchenko, Matthew J.; Reilly, Sarah-Jayne; Turner, Nicholas
errShare
errSave
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study
err2024-05-14
err1
PREAI
errCoriano, Matilde; Tommasi, Chiara; Dinh, Anh Thi Lan; Needham, Jazmine; Aziz, Hala; Joharatnam-Hogan, Nalinie; Cunningham, Niamh; Waterhouse, Jasmin; Sun, Mingze; Turkes, Fiona; Pellegrino, Benedetta; Mcgrath, Sophie; Okines, Alicia; Parton, Marina; Turner, Nicholas; Johnston, Stephen; Musolino, Antonino; Ring, Alistair; Battisti, Nicolo Matteo Luca
errShare
errSave
Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial
err2024-05-02
err1
PREAI
errHowell, Sacha; Rugo, Hope; Oliveira, Mafalda; Dalenc, Florence; Cortes, Javier; Gomez, Henry; Hu, Xichun; Jhaveri, Komal; Krivorotko, Petr; Loibl, Sibylle; Murillo, Serafin Morales; Okera, Meena; Park, Yeon; Sohn, Joo Hyuk; Toi, Masakazu; Tokunaga, Eriko; Zhukova, Lyudmila; Lloyd, Andrew; de Bruin, Elza; Egile, Coumaran; D'Cruz, Celina; Turner, Nicholas
errShare
errSave